Are NMDA antagonistic properties relevant for antiparkinsonianlike activity in rats?—Case of amantadine and memantine

The functional anatomy of basal ganglia disorders

1989 • 5,166 citations

Reversal of Experimental Parkinsonism by Lesions of the Subthalamic Nucleus

1990 • 1,875 citations

The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.

1986 • 1,814 citations

Fundamental Research Statistics for the Behavioral Sciences.

1971 • 1,600 citations

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

1990 • 1,102 citations

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

1991 • 554 citations

Role for Excitatory Amino Acids in Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity

1989 • 495 citations

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study

1991 • 303 citations

Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.

1994 • 283 citations

Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)

1993 • 278 citations

The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine‐depleted rats and MPTP‐treated monkeys

1991 • 258 citations

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

1989 • 251 citations

N-Methyl-d-Aspartate Antagonists in the Treatment of Parkinson's Disease

1991 • 221 citations

Glutamate antagonists have different effects on spontaneous locomotor activity in rats

1994 • 186 citations

Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats

1989 • 168 citations

Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats.

1989 • 164 citations

Potential Antidepressive Properties of Amantadine, Memantine and Bifemelane

1993 • 155 citations

Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease

1992 • 137 citations

Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression.

1992 • 128 citations

Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems

1990 • 123 citations

MK‐801 Fails to Protect Against the Dopaminergic Neuropathology Produced by Systemic 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mice or Intranigral 1‐Methyl‐4‐Phenylpyridinium in Rats

1992 • 120 citations

Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: A possible mode of action in Parkinson's disease

1971 • 112 citations

Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior.

1985 • 109 citations

The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way

1992 • 94 citations

On the mode of action of amantadine

1970 • 92 citations

Behavioural pharmacology of glutamate in the basal ganglia.

1992 • 90 citations

Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-D-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro.

1992 • 74 citations

Role of N-methyl-d-aspartate (NMDA) receptors in experimental catalepsy in rats

1990 • 72 citations

Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex

1993 • 68 citations

Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution

1982 • 59 citations

Neuroleptic-induced catalepsy as a model of Parkinson's disease II. Effect of glutamate antagonists

1990 • 58 citations

The effect of amantadine on motor activity and catalepsy in rats

1972 • 53 citations

Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy

1991 • 51 citations

NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists

1993 • 48 citations

In vivo labelling of the NMDA receptor channel complex by [3H]MK-801

1988 • 45 citations

Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia

1991 • 45 citations

Anticataleptic potencies of glutamate-antagonists

1991 • 41 citations

Amantadine sulphate in treating Parkinson's disease: Clinical effects, psychometric tests and serum concentrations

1989 • 38 citations

Lamotrigine-antiparkinsonian activity by blockade of glutamate release?

1993 • 37 citations

Anticataleptic actions of amantadine hydroehloride

1970 • 34 citations

Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties.

1992 • 29 citations

Amantadine in depression: Relationship between behavioural effects and plasma levels

1973 • 28 citations

Plasma and CSF levels of dizocilplne (MK-801) required for neuroprotection in the quinolinate-injected rat striatum

1991 • 19 citations

Milacemide therapy for Parkinson's disease

1993 • 17 citations

A Point Mutation in the Cl-inhibitor Gene Causes Type I Hereditary Angiooedema

1993 • 15 citations

Amantadine increases striatal dopamine turnover in MPTP‐treated mice

1993 • 14 citations

N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease.

1993 • 4 citations